The abstract is read at the publisher; the summary is JClub's.
Safimaltib (JNJ-67856633) is a selective, allosteric MALT1 inhibitor that suppresses DLBCL and MCL cell growth at sub-micromolar doses and shows efficacy in mouse models.
- Why it matters: BCR-driven non-Hodgkin lymphomas rely on MALT1-mediated NF-κB signaling, and resistance to BTK-targeted therapy motivates additional pathway-specific inhibitors.
- What they did: The team solved the safimaltib–MALT1 crystal structure, ran enzyme kinetics to define inhibition, tested lymphoma cell lines including BTK-inhibition resistance models, and evaluated DLBCL/MCL efficacy and combination with a BTK inhibitor in mice.
- The result: Activating mutations in BCR-pathway components are strongly associated with safimaltib response in vitro, and safimaltib was well tolerated in preclinical immunocompetent animals, supporting a first-in-human MALT1 inhibitor trial.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.